Stereotyped patterns of behaviour and interests · children aged 5 to 11 years with ASD
1 finding from 1 review
Total adverse events · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Non‐core symptoms of ASD · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in non‐core symptoms of ASD compared with placebo (low certainty).
1 finding from 1 review
Tolerability · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in tolerability compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Number of joint bleeding episodes per year (AJBR) · children or adults with hemophilia A or B
1 finding from 1 review
Intervention not reported
Number of total bleeds per year (ABR) · children or adults with hemophilia A or B
1 finding from 1 review
Intervention not reported
Treatment‐related adverse events · children or adults with hemophilia A or B
1 finding from 1 review
Annualized joint Bleeding Rate (AjBR) · children or adults with hemophilia A
Prophylaxis with standard therapeutic factor concentrate showed no clear difference in AJBR compared with pegylated liposome FVIII formulation (low certainty).
1 finding from 1 review
ABR · children or adults with hemophilia A
Prophylaxis with standard therapeutic factor concentrate showed no clear difference in ABR compared with pegylated liposome FVIII formulation (low certainty).
1 finding from 1 review
Any reported adverse effects · children or adults with hemophilia A
1 finding from 1 review
Number of joint bleeding episodes or joint bleeding frequency · participants with haemophilia
Prophylaxis regimen showed no clear difference in number of joint bleeding episodes or joint bleeding frequency compared with on‐demand treatment (low certainty).
1 finding from 1 review
Number of total bleeds per year or bleeding frequency · participants with haemophilia
Prophylaxis regimen showed no clear difference in number of total bleeds per year or bleeding frequency compared with on‐demand treatment (low certainty).
1 finding from 1 review
Any reported adverse events · participants with haemophilia
Prophylaxis regimen probably leads to higher any reported adverse events compared with on‐demand treatment (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) All participants Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to treatment failure (any reason related to treatment)All… compared with phenytoin (time to treatment failure) (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: focal onset seizures Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin (time to treatment failure) (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine may leads to higher time to treatment failure (any reason related to treatment)… compared with phenytoin (time to treatment failure) (low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) All participants Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to first seizure after randomisationAll participants Range of compared with phenytoin (secondary outcomes) (moderate certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) Subgroup: focal onset seizures Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to first seizure after randomisation Subgroup: focal onset… compared with phenytoin (secondary outcomes) (moderate certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) ‐ stratified by epilepsy type: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to first seizure after randomisationSubgroup: generalisedonset… compared with phenytoin (secondary outcomes) (low certainty).
1 finding from 1 review
Time to achieve 12‐month remissionAll participants Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to achieve 12‐month remissionAll participants Range of compared with phenytoin (secondary outcomes) (moderate certainty).
1 finding from 1 review